These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 17186689

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The prevalence of extended-spectrum beta lactamase-producing Escherichia coli and Klebsiella pneumoniae in clinical isolates and risk factors.
    Ozgunes I, Erben N, Kiremitci A, Kartal ED, Durmaz G, Colak H, Usluer G, Colak E.
    Saudi Med J; 2006 May; 27(5):608-12. PubMed ID: 16680246
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Extended spectrum b lactamases (ESBL) in clinical isolates of Klebsiella pneumoniae and Escherichia coli.
    Duttaroy B, Mehta S.
    Indian J Pathol Microbiol; 2005 Jan; 48(1):45-8. PubMed ID: 16758790
    [Abstract] [Full Text] [Related]

  • 8. Prevalence and significance of a negative extended-spectrum beta-lactamase (ESBL) confirmation test result after a positive ESBL screening test result for isolates of Escherichia coli and Klebsiella pneumoniae: results from the SENTRY Asia-Pacific Surveillance Program.
    Bell JM, Chitsaz M, Turnidge JD, Barton M, Walters LJ, Jones RN.
    J Clin Microbiol; 2007 May; 45(5):1478-82. PubMed ID: 17344367
    [Abstract] [Full Text] [Related]

  • 9. [In vitro activity of fosfomycin against ESBL-producing enterobacteria of urinary origin].
    Hernández MS, García JA, Muñoz JL.
    Rev Esp Quimioter; 2009 Mar; 22(1):25-9. PubMed ID: 19308743
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Extended spectrum â-lactamase producing multidrug resistant clinical bacterial isolates at National Public Health Laboratory, Nepal.
    Poudyal S, Bhatta DR, Shakya G, Upadhyaya B, Dumre SP, Buda G, Kandel BP.
    Nepal Med Coll J; 2011 Mar; 13(1):34-8. PubMed ID: 21991699
    [Abstract] [Full Text] [Related]

  • 14. [Evaluation of the Phoenix automated microbiology system for detecting extended-spectrum beta-lactamase in Escherichia coli, Klebsiella species and Proteus mirabilis].
    Lee KK, Kim ST, Hong KS, Huh HJ, Chae SL.
    Korean J Lab Med; 2008 Jun; 28(3):185-90. PubMed ID: 18594169
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. High incidence of extended-spectrum beta-lactamases among outpatient clinical isolates of Escherichia coli: a phenotypic assessment of NCCLS guidelines and a commercial method.
    Sorlózano A, Gutiérrez J, Palanca M, Soto MJ, Piédrola G.
    Diagn Microbiol Infect Dis; 2004 Oct; 50(2):131-4. PubMed ID: 15474323
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.